Our Approach
Tablet Format Designed to Unlock Patient Acceptance and Drive Superior Health Outcomes
We leverage our N-Tab™ platform, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream.
Therapeutic Areas
First-in-Class Oral Therapies in Daily Tablet Form to Address Unmet Medical Needs
EB613 (oral PTH(1-34)) is being developed as the first once-daily oral anabolic (bone forming) PTH(1-34), teriparatide tablet treatment to support earlier osteoanabolic intervention for postmenopausal women with osteoporosis at high risk for fracture.
We are developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP-2 peptide tablet for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health.
About us
Entera is Daring Courageous Fierce
Bringing together scientific excellence and drug development expertise to deliver breakthrough oral therapies
Events
Mollis odio non blandit blandit. Suspendisse ut sem vitae sem malesuada auctor vitae in dolor.
Publication and Events
Shaping the Future of Tablet-Based Therapies: From Peer-Reviewed Research to Industry Events and Publications
- June 30, 2025
Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting
- June 26, 2025
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Share chart
Lorem ipsum dolor sit amet,
In vitae orci fringilla, dignissim nulla quis, faucibus turpis. In vitae ex sapien. Suspendisse pretium porttitor tellus ac convallis.
